首页> 外文期刊>Neurology India. >Does adjunctive corticosteroid and aspirin therapy improve the outcome of tuberculous meningitis?
【24h】

Does adjunctive corticosteroid and aspirin therapy improve the outcome of tuberculous meningitis?

机译:辅助皮质类固醇和阿司匹林治疗是否改善了结核性脑膜炎的结果?

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Stroke is common in tuberculous meningitis ( TBM), and aspirin has been shown to reduce mortality. A combination of aspirin and corticosteroid may be more useful in this condition. Aim: To evaluate the effect of aspirin and corticosteroid adjunctive therapy alone or in combination in determining the outcome of TBM. Materials and Methods: One hundred and fifty-three patients with TBM were evaluated from a prospectively maintained registry. The diagnosis of TBM was based on the clinical, magnetic resonance imaging ( MRI)/ computed tomography ( CT), and cerebrospinal fluid criteria. The baseline clinical, laboratory, and radiological findings were noted. All patients received the standard 4-drug antituberculous ( rifampicin, isoniazid, pyrazinamide, and ethambutol) treatment. Group I patients received in addition, aspirin, in the dose of 150 mg daily; group II patients received aspirin 150 mg plus prednisolone 40 mg daily; and, group III patients received none of these adjunctive therapies. The outcome at 3 months was defined in terms of death or functional disability. Results: Group I had 44, group II had 50, and group III had 41 patients. The baseline characteristics of all these patients were similar, except in group II, where patients had more severe meningitis and focal deficits compared to the patients in group I and III. At 3 months, 32 ( 23%) patients died; 8 ( 18.2%) in group I, 9 ( 18%) in group II, and 14 ( 34.1%) in group III. There was insignificant survival benefit in group II ( hazard ratio [ HR], 1.55; 95% confidence interval ( CI), 0.96- 26.49; P = 0.07). The three-month functional outcome and side effects were not significantly different in the three groups. Conclusion: Aspirin with corticosteroid adjunctive treatment seems to be beneficial in reducing mortality in TBM.
机译:背景:中风在结核性脑膜炎(TBM)中常见,并且已显示阿司匹林降低死亡率。阿司匹林和皮质类固醇的组合在这种情况下可能更有用。目的:评价阿司匹林和皮质类固醇辅助治疗单独的影响或组合在确定TBM的结果时。材料和方法:从前瞻性维持的登记处评估一百五十三名TBM患者。 TBM的诊断基于临床,磁共振成像(MRI)/计算断层扫描(CT)和脑脊液标准。注意到基线临床,实验室和放射性发现。所有患者均接受标准的4-药物抗核使(利福平,异烟肼,吡嗪酰胺和乙胺醇)处理。 IACLA患者另外,阿司匹林,每日150毫克的剂量;第II族患者接受阿司匹林150毫克加上泼尼松龙每日40毫克;而且,第三组患者没有任何辅助疗法。 3个月的结果是在死亡或功能残疾方面定义的。结果:I组44,II组有50个,第III族有41名患者。除II组中,所有这些患者的基线特征是相似的,与I族和III组患者相比,患者患者具有更严重的脑膜炎和局灶性缺陷。 3个月,32例(23%)患者死亡; II族第I,9(18%)的8(18.2%),III组中的14名(34.1%)。 II族(危害比[HR],1.55; 95%置信区间(CI),0.96-26.49; P = 0.07)存在微不足道的存活效果。三个群体的三个月功能结果和副作用没有显着差异。结论:具有皮质类固醇辅助治疗的阿司匹林似乎有益降低TBM的死亡率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号